The Oxford/AstraZeneca Covid-19 vaccine does not appear to offer protection against mild and moderate disease caused by the viral variant first identified in South Africa, according to a study due to be published on Monday.
根据将于周一公布的一项研究，牛津/阿斯利康(Oxford/AstraZeneca)新型冠状病毒疫苗对最早在南非发现的变异病毒引发的轻中症似乎不具保护效力。
Although none of the more than 2,000 patients in the study died or was hospitalised, the findings, which have not yet been peer reviewed, could complicate the race to roll out vaccines as new strains emerge.
尽管参与该研究的逾2000名患者无一死亡或住院，但随着新毒株的出现，这一研究结果可能使得推出疫苗的竞赛变得更加复杂。该研究尚未经过同行评议。
In both the human trials and tests on the blood of those vaccinated, the jab showed significantly reduced efficacy against the 501Y.V2 viral variant, which is dominant in South Africa, according to the randomised, double-blind study seen by the Financial Times.
根据英国《金融时报》看到的这项随机双盲研究，在人体试验和针对接种者的血液试验中，该疫苗对南非流行的501Y.V2变体的有效性明显降低。
“A two-dose regimen of [the vaccine] did not show protection against mild-moderate Covid-19 due to [the South African variant]”, the study says, adding that efficacy against severe Covid-19, hospitalisations and deaths was not yet determined.
该研究表示：“接种两剂（该疫苗）的方案没有对由（南非变异病毒）引发的轻中症新冠肺炎显示出保护效力。”该研究补充称，还不确定该疫苗对重症、住院和死亡病例的有效性。
The so-called Kent variant — which Oxford university said on Friday was just as susceptible to the vaccine as older variants of the virus — has now acquired the E484K mutation, which is present in the variants fuelling Covid-19 surges in Brazil and South Africa.
牛津大学周五表示，其疫苗对在英国发现的所谓肯特变体(Kent variant)与对更早出现的变体一样有效。而肯特变体目前已出现E484K突变，造成巴西和南非新冠肺炎感染病例激增的变体中都出现了这种突变。